Cabometyx (cabozantinib) — Medica
Neuroendocrine tumors
Initial criteria
- age ≥ 12 years
- disease is locally advanced, unresectable, or metastatic
- EITHER well-differentiated neuroendocrine tumors OR (tumor type is pancreatic or extra-pancreatic neuroendocrine tumor AND use is as subsequent therapy)
Approval duration
1 year